Home / Resources / Preclinical resources

前臨床

注目コンテンツ

Understanding and Calculating Steady State Pharmacokinetics

Blog, Knowledge Base

Upcoming preclinical webinars

ウェビナー

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

Mar 17, Apr 2 – 11am - 12pm ET

ウェビナー

Explore Smarter, Faster PK/PD with Phoenix

2026年3月17日 – 10-11 AM ET/CET/JST

ウェビナー

Portfolio Prioritization for Large and Small Pharma Using Early-Stage Biosimulation

Mar 24, Apr 2

Latest preclinical blogs

All Preclinical - Blog

Blog

PBPKモデル化による生物学的同等性評価およびジェネリック医薬品承認の支援

以下のイベントで弊社のエキスパートをご紹介

展示会・学会

ACDM 2026

March 15 - 17, 2026 – Berlin, Germany – Booth 13

展示会・学会

SOT Annual Meeting and ToxExpo 2026

March 22 - 25, 2026 – San Diego, CA – Booth 2024

展示会・学会

Quantitative Systems Pharmacology Conference

April 8 - 10, 2026

All preclinical resources

Where Did the 80-125% Bioequivalence Criteria Come From?

Modeling and Simulation - PK/PD, Blog, Knowledge Base

Generics and Bioequivalence

Modeling and Simulation - PK/PD, pre-update, Knowledge Base

What are Compartmental Models?

Modeling and Simulation - PK/PD, Knowledge Base

What are Drug-drug Interactions Anyway?

Modeling and Simulation - PK/PD, pre-update, Knowledge Base

Absorption Rate

Modeling and Simulation - PK/PD, pre-update, Knowledge Base

PBPK Modeling of Inter-individual Variability in the Pharmacokinetics of Environmental Chemicals

Certara Products - Simcyp, Modeling and Simulation - PBPK, pre-update, Publication

What is a Half-life?

Modeling and Simulation - PK/PD, pre-update, Knowledge Base

Incorporating Human Dosimetry and Exposure into High-throughput In Vitro Toxicity Screening

Model Informed Drug Development, pre-update, Publication

Mechanistic Toxicokinetic Model for γ-Hydroxybutyric Acid: Inhibition of Active Renal Reabsorption as a Potential Therapeutic Strategy

Model Informed Drug Development, pre-update, Publication

Confidence Assessment of Predicting Clinical Drug Interactions of Mechanism-based CYP3A Inhibitors Using Simcyp Time-based Approach and a Static Mathematic Model

Model Informed Drug Development, pre-update, Publication

What Does Clearance Mean?

Modeling and Simulation - PK/PD, pre-update, Knowledge Base

Understanding Volume of Distribution

サターラの製品 - Phoenix、モデリングおよびシミュレーション - PK/PD、ブログ、ナレッジベース

ニュースレターを購読

今すぐ登録：医薬品開発の革新は、サターラの情熱そのものです。最新情報を入手し、ともに科学の限界を切り拓いていきましょう。

前臨床

最新のリソース

ADC Development & Differentiation Strategies | Quantitative Systems Pharmacology & MIDD

Certara Announces 2026 Certainty Event

Certara Expands Simcyp® Simulator to Streamline Regulatory Submissions and Internal Efficiencies

注目コンテンツ

Understanding and Calculating Steady State Pharmacokinetics

Upcoming preclinical webinars

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

Explore Smarter, Faster PK/PD with Phoenix

Portfolio Prioritization for Large and Small Pharma Using Early-Stage Biosimulation

Latest preclinical blogs

医薬品開発におけるPK/PDモデリングのための機械学習

米国FDAのモデルに基づく医薬品開発と対になったパイロットプログラムが治験依頼者を助ける方法

Gain Nonclinical Drug Safety Insights with Real-Time Data Analysis

指標となる臨床的薬剤相互作用研究における代謝物の測定

Key development considerations for cell therapies

PBPKモデル化による生物学的同等性評価およびジェネリック医薬品承認の支援

以下のイベントで弊社のエキスパートをご紹介

ACDM 2026

SOT Annual Meeting and ToxExpo 2026

Quantitative Systems Pharmacology Conference

All preclinical resources

Where Did the 80-125% Bioequivalence Criteria Come From?

Generics and Bioequivalence

What are Compartmental Models?

What are Drug-drug Interactions Anyway?

Absorption Rate

PBPK Modeling of Inter-individual Variability in the Pharmacokinetics of Environmental Chemicals

What is a Half-life?

Incorporating Human Dosimetry and Exposure into High-throughput In Vitro Toxicity Screening

Mechanistic Toxicokinetic Model for γ-Hydroxybutyric Acid: Inhibition of Active Renal Reabsorption as a Potential Therapeutic Strategy

Confidence Assessment of Predicting Clinical Drug Interactions of Mechanism-based CYP3A Inhibitors Using Simcyp Time-based Approach and a Static Mathematic Model

What Does Clearance Mean?

Understanding Volume of Distribution

メルマガ登録

クイックアクセス

ソリューション

お問合せ